Cyclerion Therapeutics Inc. (CYCN) said that it has reached a global license agreement with Akebia Therapeutics Inc., a biopharmaceutical company focused on kidney disease, for the development and commercialization of praliciguat, an oral sGC stimulator.
As per the terms of the deal, Akebia has obtained an exclusive license to research, develop and commercialize praliciguat globally and will be solely responsible for these activities going forward.
Cyclerion is eligible to receive up to $225 million in pre-commercial milestones, including up to $15 million in the first 18 months. Total potential future development, regulatory, and commercialization milestone payments could result in up to $585 million. Cyclerion is also eligible to receive tiered, sales-based royalties ranging from single-digit to high-teen percentages.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.